Exact Sciences stock price target lowered to $46 at RBC on growth concerns

Published 07/08/2025, 16:40
Exact Sciences stock price target lowered to $46 at RBC on growth concerns

Investing.com - RBC Capital has lowered its price target on Exact Sciences (NASDAQ:EXAS) to $46.00 from $54.00 while maintaining a Sector Perform rating on the stock. The new target represents the low end of analyst expectations, with targets ranging from $46 to $90. According to InvestingPro data, the stock currently trades at $41.76 and appears undervalued based on its Fair Value analysis.

The price target reduction comes despite Exact Sciences reporting strong quarterly results, with approximately $40 million in revenue beat and a $55 million increase to its full-year 2025 guidance, which included about $8 million in license revenue. The company has maintained solid revenue growth of 12.56% over the last twelve months, though it remains unprofitable during this period.

RBC analyst commentary indicates the downgrade stems from concerns about Exact Sciences’ "ability to be a long-term competitor in blood-based liquid biopsy testing" following the company’s decision to acquire a competitive screening test after experiencing poor data from its own test.

The investment firm has adjusted its target multiple on the stock to reflect what it describes as a total addressable market (TAM) that is "essentially 1/3 of what it was yesterday."

RBC’s new price target is based on updated calendar year 2026 estimates for Exact Sciences, while the firm maintains its Sector Perform rating on the stock.

In other recent news, Exact Sciences reported impressive second-quarter 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.01, which was significantly better than the anticipated -$0.13, resulting in a 92.31% EPS surprise. Revenue also exceeded forecasts, reaching $811.1 million compared to the expected $773.8 million, marking a 4.82% surprise. Despite these strong financial results, TD Cowen lowered its price target for Exact Sciences to $66 from $75, while maintaining a Buy rating, citing a blood test setback. Piper Sandler, on the other hand, reiterated its Overweight rating and maintained a $70 price target, emphasizing the company’s strong position in colorectal cancer screening and the shift towards noninvasive detection methods. These developments highlight the mixed analyst perspectives on Exact Sciences following its recent performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.